Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYL-1401O + taxane
- Development stage
- Unknown
- Lead developer
- Viatris
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
MYL-1401O + taxane is a combination therapy consisting of the trastuzumab biosimilar MYL-1401O (marketed as Ogivri, generic name trastuzumab-dkst) in combination with a taxane chemotherapy agent (commonly docetaxel or paclitaxel). MYL-1401O is a biosimilar of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Taxanes are a class of chemotherapeutic agents that disrupt microtubule function to inhibit cell division. This combination is primarily used as first-line or palliative therapy in HER2-positive metastatic or early-stage breast cancer and has demonstrated efficacy and safety equivalent to the reference trastuzumab (Herceptin) plus taxane regimens in both clinical trials and real-world settings. The combination exerts its effect by antagonizing HER2 receptor signaling (trastuzumab component) and promoting cell death by microtubule disruption (taxane component)[1][2][3][4][6][7][9][10].
- Brand names
- Ogivri
- Other names
- trastuzumab-dkst + taxaneMYL-1401O + docetaxelMYL-1401O + paclitaxel
02
Targets
MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MYL-1401O + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYL-1401O + taxane.